New drug cocktail may turn inoperable stomach cancer into operable disease
NCT ID NCT05177068
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 29 times
Summary
This study tests whether a combination of three drugs (fruquintinib, sintilimab, and SOX chemotherapy) can shrink advanced stomach cancer enough to allow surgical removal. About 42 adults with stage IV gastric cancer that has spread to nearby organs or lymph nodes will receive the treatment before surgery. The main goal is to see how many patients achieve complete tumor removal with clear margins.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.